Bellevue Group AG cut its stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 19.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 205,239 shares of the company's stock after selling 48,943 shares during the quarter. Bellevue Group AG owned about 0.36% of Astrana Health worth $6,471,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of ASTH. Barclays PLC purchased a new stake in shares of Astrana Health in the 3rd quarter valued at approximately $4,457,000. Franklin Resources Inc. acquired a new position in Astrana Health in the third quarter valued at about $1,187,000. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health during the third quarter valued at about $13,383,000. Linden Thomas Advisory Services LLC lifted its stake in Astrana Health by 23.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 15,247 shares of the company's stock worth $481,000 after purchasing an additional 2,883 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Astrana Health by 108.4% during the fourth quarter. KBC Group NV now owns 2,530 shares of the company's stock worth $80,000 after buying an additional 1,316 shares during the period. Institutional investors and hedge funds own 52.77% of the company's stock.
Astrana Health Stock Performance
ASTH traded down $3.57 on Friday, reaching $29.87. The company had a trading volume of 179,989 shares, compared to its average volume of 280,424. The stock has a 50-day moving average price of $30.84 and a 200-day moving average price of $36.59. The stock has a market capitalization of $1.67 billion, a PE ratio of 22.98, a P/E/G ratio of 1.37 and a beta of 1.00. Astrana Health, Inc. has a 1 year low of $23.12 and a 1 year high of $63.20. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.14). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period last year, the firm earned $0.31 earnings per share. The business's quarterly revenue was up 53.4% compared to the same quarter last year. As a group, research analysts forecast that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on ASTH shares. Robert W. Baird decreased their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Barclays assumed coverage on shares of Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price on the stock. Stifel Nicolaus lowered their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Bank of America reduced their price target on Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Truist Financial lowered their price objective on Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $53.29.
View Our Latest Report on Astrana Health
About Astrana Health
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
